Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03773965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Study acronym: JUVE-X
StatusRecruiting
PhasePhase 3
Started2019-04-05
View on ClinicalTrials.gov ↗
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Amendment record

Amended 121 times since 2018-12-11; most recent filed 2026-08-21. The 50 most recent of 122 record versions are listed below. See every version on ClinicalTrials.gov ↗

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-21
Amendment Study Status, Contacts/Locations v121
2026-08-06
Amendment Study Status, Contacts/Locations v120
2026-07-16
Amendment Study Status, Contacts/Locations v119
2026-06-19
Amendment Study Status, Contacts/Locations v118
2026-05-11
Amendment Study Status, Contacts/Locations v117
2026-02-09
Amendment Study Status, Contacts/Locations v116
2026-01-19
Amendment Study Status, Contacts/Locations v115
2026-01-12
Amendment Study Status, Contacts/Locations v114
2025-12-05
Amendment Study Status v113
2025-11-21
Amendment Study Status, Contacts/Locations v112
2025-11-04
Amendment Study Status, Contacts/Locations v111
2025-09-22
Amendment Study Status, Contacts/Locations v110
2025-08-21
Amendment Study Status, Contacts/Locations v109
2025-07-22
Amendment Study Status, Contacts/Locations v108
2025-07-07
Amendment Study Status, Contacts/Locations v107
2025-05-20
Amendment Study Status, Contacts/Locations v106
2025-02-11
Amendment Study Status, Contacts/Locations v105
2024-12-02
Amendment Study Status, Contacts/Locations v104
2024-09-22
Amendment Study Status, Contacts/Locations v103
2024-08-25
Amendment Study Status, Contacts/Locations v102
2024-07-18
Amendment Study Status, Contacts/Locations v101
2024-05-21
Amendment Study Status, Contacts/Locations v100
2024-04-16
Amendment Study Status, Contacts/Locations v99
2024-02-27
Amendment Study Status, Contacts/Locations v98
2024-01-12
Amendment Study Status, Contacts/Locations v97
2023-10-09
Amendment Study Status, Contacts/Locations v96
2023-09-13
Amendment Study Status, Contacts/Locations v95
2023-06-09
Amendment Study Status, Contacts/Locations v94
2023-03-24
Amendment Study Status, Contacts/Locations v93
2023-03-04
Amendment Study Status v92
2023-02-22
Amendment Study Status v91
2023-02-13
Amendment Study Status v90
2023-01-18
Amendment Study Status v89
2023-01-12
Amendment Study Status v88
2022-12-27
Amendment Study Status, Contacts/Locations v87
2022-12-09
Amendment Study Status, Contacts/Locations v86
2022-11-24
Amendment Study Status v85
2022-11-10
Amendment Study Status, Contacts/Locations v84
2022-10-18
Amendment Study Status v83
2022-10-10
Amendment Study Status v82
2022-09-19
Amendment Study Status v81
2022-09-08
Amendment Study Status, Contacts/Locations v80
2022-08-17
Amendment Study Status v79
2022-08-08
Amendment Study Status, Contacts/Locations v78
2022-06-21
Amendment Study Status, Contacts/Locations v77
2022-06-08
Amendment Study Status, Contacts/Locations v76
2022-05-19
Amendment Study Status, Contacts/Locations v75
2022-05-10
Amendment Study Status, Contacts/Locations v74
2022-03-08
Amendment Study Status, Contacts/Locations v73
2022-01-18
Amendment Study Status, Contacts/Locations v72
Trial Details
NCT Number NCT03773965
Lead Sponsor Eli Lilly and Company
Conditions Juvenile Idiopathic Arthritis
Enrollment 190 participants
Start Date 2019-04-05
Primary Completion 2031-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-24